Jean-Charles Soria, MD

Jean-Charles Soria, MD

Professor of Medicine and Medical Oncology
South-Paris University
Cancer Specialist
Institut Gustave Roussy (IGR)
Paris, France

Related Videos

What is the role of NGS-based molecular profiling for providing roadmaps suggesting how combination, targeted therapy can produce improved clinical outcomes? Video

What is the role of NGS-based molecular profiling for providing roadmaps suggesting how combination, targeted therapy can produce improved clinical outcomes?

What is the role of NGS-based molecular profiling for providing roadmaps suggesting how combination, targeted therapy can produce improved clinical outcomes?

In your practice, how early do you recommend performing whole exome sequencing and in what tumors, and is it critical to detect mutations, translocations, allelic fractions, and amplifications? Video

In your practice, how early do you recommend performing whole exome sequencing and in what tumors, and is it critical to detect mutations, translocations, allelic fractions, and amplifications?

In your practice, how early do you recommend performing whole exome sequencing and in what types of tumors, and is it critical to detect mutations, translocations, allelic fractions, and amplifications?

From a precision medicine perspective, how should we be integrating and incorporating ctDNA profiling — i.e., liquid biopsies — with tissue-based whole exome NGS, including longitudinal biopsies? Video

From a precision medicine perspective, how should we be integrating and incorporating ctDNA profiling — i.e., liquid biopsies — with tissue-based whole exome NGS, including longitudinal biopsies?

From a precision medicine perspective, how should we be integrating and incorporating ctDNA profiling — i.e., liquid biopsies — with tissue-based whole exome NGS, including longitudinal biopsies?

What are the implications of FDA approval of PD-1 inhibitors for MSI-high tumors, and what other molecular alterations might trigger immunotherapy based on NGS-generated markers and drivers agnostic to tumor type? Video

What are the implications of FDA approval of PD-1 inhibitors for MSI-high tumors, and what other molecular alterations might trigger immunotherapy based on NGS-generated markers and drivers agnostic to tumor type?

What are the implications of FDA approval of PD-1 inhibitors for MSI-high tumors, and what other canonical molecular alterations —NTRK and others — do you see on the horizon that might trigger immunotherapy based on NGS-generated markers ...

Given some of the conflicting results reported by precision medicine trials, how do you reconcile some of the divergent results and their implications for NGS-based molecular stratification? Video

Given some of the conflicting results reported by precision medicine trials, how do you reconcile some of the divergent results and their implications for NGS-based molecular stratification?

Given some of the conflicting results reported by precision medicine trials, how do you reconcile some of the divergent results and their implications for NGS-based molecular stratification?